» RELATED: Not ready for kids? New, affordable at-home fertility test gives women better data on eggs, fertility timeline
The National Society of Genetic Counselors echoed St. Pierre's statement in a blog post and added that "consumers who test positive for these mutations need to be retested in a clinical setting under the supervision of a medical professional before moving forward with any medical decisions."
Breast cancer is the most common cancer in American women and the second-biggest killer, after lung cancer. According to the American Cancer Society, 260,000 women and a few men will be diagnosed with breast cancer in 2018 and nearly 41,000 will die as a result of breast cancer.
A 23andMe spokeswoman said the test will be added to its services "in the coming weeks" with no increase to the current $199 cost, CNN reported.
» RELATED: Major study identifies 72 new genetic risk factors for breast cancer
In 2015, the FDA approved 23andMe’s test for customers to show whether they are carriers of certain disease-carrying genes that could be passed on to their children.
Last year, the company was also granted approval to issue genetic health risk reports.
23andMe CEO and founder Anne Wojcicki thanked the FDA on Twitter Tuesday for their “hard work and progress on innovation.”
More from the FDA’s approval at fda.gov.